Galaxy medicare limited IPO Overview
Galaxy medicare limited IPO is a SME public issue offered through a Book Building issue with a total issue size of ₹— crores. The IPO price band is set at ₹51 to ₹54 per share, and retail investors can apply with a minimum investment of ₹2.16 L as per IPO guidelines.
The Galaxy medicare limited IPO opens on 10 Sept 2025 and closes on 12 Sept 2025. The IPO allotment is expected to be finalized on 15 Sept 2025, and the equity shares are proposed to be listed on NSE on 17 Sept 2025.
Investors can refer to the Galaxy medicare limited IPO RHP-DRHP for detailed information. The issue is managed by Affinity Global Capital Market Pvt.Ltd. as the book running lead manager, while Cameo Corporate Services Limited is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About galaxy medicare limited
The company manufactures these products using premium grade raw material that is procured from the authentic vendors of the market.
The company specializes in various products, including surgical dressings, plaster of Paris bandages, adhesive tapes, compression bandages, and wound care solutions.
Their offerings meet diverse medical needs, including gauze products and orthopedic items.
The company's business includes the following:-
Manufacturing and branding for flagship brands: POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE, GYPSONET, GYPSOCHLOR, FIXCAN ETC.;
OEMs source components, design, manufacture, and test quality according to brand owners' specifications under Principal-to-Principal basis;
Institutional sales via government tenders on GEM Portal;
Exporting its products internationally and trading surgical devices dressings.
The company has 27 registered trademarks in India, serving domestic and international markets.
The company's products are accepted by the medical community and supplied throughout India to government health departments, corporate hospitals, and private entities.
The company complies with ISO 9001:2015 and ISO 13485:2016 certifications, ensuring that its products meet the rigorous demands of healthcare institutions.
As of March 2025, the company has 190 employees in various departments.
Competitive Strength:
Experienced Leadership and Skilled Management Team.
Established reputation and customer relationships.
Focus on consistently meeting quality standards.
Well Established Manufacturing Facility with Wide Range of Products.
In-house Quality Assurance (QA) / Quality Control (QC) and Research & Development for quality control.
International market Presence.
Investment Objective
Funding the working capital requirements
General Corporate Purposes
To meet the offer related expenses